What Is Inflammaging? Chronic Inflammation and Aging
Inflammaging is the slow rise in baseline inflammatory signalling with age. Where it comes from, how it is measured, and what lowers it.
The Short Answer
Inflammaging is the chronic, low-grade, sterile elevation of inflammatory signalling that develops with age in the absence of infection. It is measured as a modest but persistent rise in circulating markers, most commonly interleukin-6, C-reactive protein and tumour necrosis factor alpha, at concentrations far below those of acute infection and sustained over years. The term was introduced in 2000 by Claudio Franceschi, and the reason it matters is that the elevation is not a passive consequence of aging: in large cohorts, higher baseline inflammatory markers independently predict frailty, cognitive decline, cardiovascular events and all-cause mortality, which places inflammaging among the mechanisms of aging rather than among its symptoms.
The Definition, Precisely
Three qualifiers in the definition carry the meaning.
Chronic. Acute inflammation is a resolving response to a specific insult, and it is protective. Inflammaging does not resolve, and the failure of resolution, rather than the initiation of the response, is increasingly seen as the central defect.
Low-grade. The magnitude is small. C-reactive protein in inflammaging sits in the range of one to three milligrams per litre, against fifty or more in acute infection. This is why standard clinical reference ranges miss it: the values are within normal limits and the trajectory across decades is not.
Sterile. No pathogen drives it. The stimuli are endogenous: cellular debris, misplaced mitochondrial DNA, senescent cell secretions, translocated gut bacterial components. Collectively these are damage-associated molecular patterns, and they engage the same receptors that detect pathogens.
Where It Comes From
Several sources contribute, and their relative weight differs between individuals, which is part of why single-target interventions disappoint.
- Senescent cells. Their secretory phenotype is an inflammatory mixture of cytokines, chemokines and matrix-degrading enzymes. A small population produces effects out of proportion to its size, and this is probably the single largest identified contributor.
- Mitochondrial dysfunction. Damaged mitochondria release DNA into the cytoplasm, where the cGAS-STING pathway recognises it as foreign and mounts an interferon response. Impaired mitophagy therefore feeds inflammation directly.
- Visceral adipose tissue. Metabolically active and populated by inflammatory macrophages, it is a substantial source of interleukin-6 and TNF-alpha. Visceral fat mass tracks inflammatory markers better than body mass index does.
- Gut barrier permeability. Increased translocation of bacterial lipopolysaccharide engages TLR4 and produces sustained low-level signalling. This is one of the more actionable contributors.
- Immunosenescence. The aging immune system loses naive T cell diversity and accumulates exhausted, pro-inflammatory memory populations, so it becomes simultaneously less capable against new challenges and more inflammatory at baseline.
- Chronic viral load. Persistent cytomegalovirus infection in particular is associated with a substantial share of the T cell repertoire being committed to its control.
- Lifestyle inputs. Sleep restriction, physical inactivity, psychological stress and periodontal inflammation each raise circulating markers measurably.
How It Is Measured
The practical markers are ordinary and their interpretation is not.
High-sensitivity CRP. Widely available, cheap, and the usual first look. It is an acute-phase protein, so a value elevated by a cold, a dental infection or a hard training session says nothing about baseline. A single reading is close to uninformative; three readings at least two weeks apart, none within two weeks of illness, establish a baseline.
Interleukin-6. Upstream of CRP and arguably the better marker of the underlying process, though less standardised across laboratories and more variable within a day.
TNF-alpha. Mechanistically central, and awkward to measure reliably in circulation because concentrations are low and short-lived.
Composite and cellular measures. Neutrophil-to-lymphocyte ratio from a standard blood count is crude and free. Some second-generation epigenetic clocks incorporate inflammatory markers directly, which is part of why they outperform first-generation clocks on outcome prediction.
The interpretive rule that matters: the trend across years is the signal, and any single value is dominated by whatever happened in the preceding fortnight.
What Lowers It
The interventions with human evidence are mostly structural rather than pharmacological.
Regular exercise. The best established. Both aerobic and resistance training lower baseline inflammatory markers over months, partly through visceral fat reduction and partly through direct effects on muscle-derived signalling. Acutely, hard exercise raises markers, which is why timing of measurement matters.
Visceral fat reduction. Directly removes a major source. This is the mechanism through which most successful dietary interventions act.
Sleep sufficiency. Experimental sleep restriction raises interleukin-6 and CRP within days in healthy volunteers, and the effect reverses on recovery sleep. Few interventions have such a short causal loop.
Dietary pattern. Mediterranean-pattern diets lower inflammatory markers in randomised trials. Omega-3 fatty acids at gram-level doses have a modest, replicated effect. Fibre intake supports the gut barrier contribution.
Oral health. Periodontal inflammation is a genuine and frequently overlooked contributor, and its correction lowers systemic markers.
What is weaker. Most antioxidant supplements do not lower inflammatory markers meaningfully. Curcumin and omega-3s have the best supplement-level evidence and their effect sizes are modest against the structural interventions. Senolytics target the largest identified source and have no human outcome evidence yet.
The Complication Worth Knowing
Inflammation is not simply bad, and interventions that suppress it broadly have costs.
The immune response is required. Long-term broad immunosuppression to lower baseline markers trades a slow signal for an acute vulnerability, and the trial history of anti-inflammatory drugs in aging populations reflects this: canakinumab, an interleukin-1beta antibody, lowered cardiovascular events in a large trial and increased fatal infection.
The more promising direction is not suppression but resolution. Acute inflammation normally terminates through an active programme involving specialised pro-resolving mediators derived from omega-3 fatty acids, and that programme appears to become less effective with age. Restoring resolution, rather than blocking initiation, is the conceptually cleaner target and is early-stage research.
Which is why the practical advice comes back to removing sources: less visceral fat, better sleep, more movement, a competent gut barrier, healthy gums. Unglamorous, and it addresses the inputs rather than blunting the response.
The AEONNN Perspective
Inflammaging is the substance of Inflammation and Immune Defense, Pillar 3, and it is the clearest case for why AEONNN's Pillars are systems rather than markers. A member does not act on interleukin-6. They act on the six or seven sources feeding it, and which of those dominates differs between people.
This is where Discovered and Synched modes diverge usefully. In Discovered mode, Insight Protocol infers likely contributors from what it can see: sleep patterns, training load, reported dietary pattern, waist measurement. In Synched mode, with hs-CRP and ideally interleukin-6 available across multiple draws, it can weight the sources rather than infer them, and the resulting recommendation set is materially different.
The Population layer, drawing on UK Biobank and NHANES data, supplies the outcome associations that justify attention to the marker at all, and the Safety layer is what prevents the obvious mistake. Suppressing an inflammatory response is not the same as removing its causes, and a platform that optimised a marker without that distinction would recommend exactly the wrong thing.
Pillar Matrix mapping
Inflammation and Immune Defense, Longevity and Biological Age
Database Matrix layers
- Mechanistic Layer (KEGG, Reactome, UniProt)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Population Layer (UK Biobank, NHANES)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
Frequently Asked
What is inflammaging in simple terms?
The slow rise in background inflammatory signalling that happens with age without any infection driving it. The levels are far below those of acute illness but persist for years, and higher baseline levels predict frailty, cognitive decline and mortality in large cohorts.
What causes inflammaging?
Several sources at once: senescent cell secretions, mitochondrial DNA leaking into the cytoplasm, visceral fat tissue, increased gut barrier permeability, age-related immune remodelling, chronic viral load, and lifestyle inputs including poor sleep and inactivity.
How is inflammaging measured?
Most commonly high-sensitivity CRP, with interleukin-6 arguably a better read on the underlying process. Any single value is dominated by recent illness or hard exercise, so three readings at least two weeks apart are needed to establish a baseline.
What CRP level indicates inflammaging?
Persistently in the range of one to three milligrams per litre, which falls within standard clinical reference ranges. That is precisely why it is missed: the individual values look normal and the multi-decade trajectory does not.
What is the best way to lower chronic inflammation?
Regular exercise has the strongest evidence, followed by visceral fat reduction, sufficient sleep, a Mediterranean-pattern diet and correction of periodontal inflammation. These act by removing sources rather than by blunting the response.
Do anti-inflammatory supplements help?
Modestly at best. Omega-3 fatty acids at gram-level doses and curcumin have the best evidence among supplements, and their effect sizes are small compared with exercise and visceral fat reduction. Most antioxidant supplements do not move the markers.
Is lowering inflammation always good?
No. The immune response is required, and broad long-term suppression trades a slow signal for acute vulnerability. In one large trial an interleukin-1beta antibody lowered cardiovascular events and increased fatal infection.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.